GEODE CAPITAL MANAGEMENT, LLC - HTG MOLECULAR DIAGNOSTICS IN ownership

HTG MOLECULAR DIAGNOSTICS IN's ticker is HTGM and the CUSIP is 40434H104. A total of 18 filers reported holding HTG MOLECULAR DIAGNOSTICS IN in Q2 2017. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
GEODE CAPITAL MANAGEMENT, LLC ownership history of HTG MOLECULAR DIAGNOSTICS IN
ValueSharesWeighting
Q3 2020$127,000
-54.2%
385,6450.0%0.00%
Q2 2020$277,000
+121.6%
385,6450.0%0.00%
Q1 2020$125,000
-76.9%
385,645
-50.0%
0.00%
Q4 2019$540,000
+227.3%
771,290
+216.6%
0.00%
Q3 2019$165,000
-59.2%
243,6330.0%0.00%
Q2 2019$404,000
-32.2%
243,633
+2.2%
0.00%
Q1 2019$596,000
-46.1%
238,453
-45.3%
0.00%
Q4 2018$1,106,000
+15.7%
435,930
+130.1%
0.00%
Q3 2018$956,000
+54.9%
189,4930.0%0.00%
Q2 2018$617,000
-6.5%
189,493
+3.9%
0.00%
Q1 2018$660,000
+1550.0%
182,401
+818.5%
0.00%
Q4 2017$40,000
+21.2%
19,8590.0%0.00%
Q3 2017$33,000
-36.5%
19,8590.0%0.00%
Q2 2017$52,000
-62.0%
19,8590.0%0.00%
Q1 2017$137,000
+211.4%
19,8590.0%0.00%
Q4 2016$44,000
-4.3%
19,8590.0%0.00%
Q3 2016$46,000
-9.8%
19,8590.0%0.00%
Q2 2016$51,000
-8.9%
19,8590.0%0.00%
Q1 2016$56,000
-34.9%
19,8590.0%0.00%
Q4 2015$86,000
-43.0%
19,8590.0%0.00%
Q3 2015$151,00019,8590.00%
Other shareholders
HTG MOLECULAR DIAGNOSTICS IN shareholders Q2 2017
NameSharesValueWeighting ↓
Novo Holdings A/S 1,280,185$9,755,0001.01%
Cormorant Asset Management, LP 201,000$1,532,0000.24%
PUTNAM INVESTMENTS LLC 575,692$4,386,0000.01%
Alyeska Investment Group, L.P. 114,113$870,0000.01%
VANGUARD GROUP INC 4,355,424$131,473,0000.01%
BLACKROCK ADVISORS LLC 463,200$3,530,0000.00%
OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) 26,100$199,000,0000.00%
Ironwood Financial, llc 870$7,0000.00%
PANAGORA ASSET MANAGEMENT INC 24,293$185,0000.00%
Sonora Investment Management, LLC 500$3,0000.00%
View complete list of HTG MOLECULAR DIAGNOSTICS IN shareholders